Related Experiment Video
Updated: Aug 5, 2026

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
Cannabis Use During Early Pregnancy and Child Diagnoses of Depressive and Anxiety Disorders
Kelly C Young-Wolff1,2,3, Mahlet Shenkute1, Nina Oberman1
1Division of Research, Kaiser Permanente Northern California.
Insights
Prenatal cannabis use did not increase the risk of anxiety or depressive disorders in children. This large study found no association between early pregnancy cannabis exposure and offspring mental health diagnoses.
Area of Science:
- Obstetrics and Gynecology
- Child and Adolescent Psychiatry
- Public Health
Background:
- Prenatal cannabis exposure is linked to adverse pregnancy outcomes.
- Limited research exists on the association between prenatal cannabis use and child anxiety or depressive disorders.
Purpose of the Study:
- To investigate the hypothesis that prenatal cannabis use is associated with child anxiety or depressive disorder diagnoses.
- To examine the relationship between early pregnancy cannabis exposure and offspring mental health outcomes.
Main Methods:
- Population-based retrospective birth cohort study (N=115,553 children).
- Screening for prenatal cannabis use (self-report or toxicology for delta-9-tetrahydrocannabinol [THC]).
- Cox proportional hazards regression models analyzed associations with child anxiety/depressive disorders (ages 6-13).
Main Results:
- Prenatal cannabis use was associated with a lower risk of child anxiety disorders (aHR:0.84, 95%CI:0.75-0.95) when defined by toxicology.
- No significant association was found for self-reported use or for depressive disorders.
- Maternal prenatal cannabis use was not linked to increased risk of child depressive disorders (aHR:1.15, 95%CI:0.85-1.54).
Conclusions:
- Prenatal cannabis use in early pregnancy was not associated with an increased risk of offspring anxiety disorders.
- The study found no association between prenatal cannabis exposure and early onset of child depressive disorders.
Objective:
Prenatal cannabis use is associated with adverse pregnancy and neonatal outcomes, but research on its association with child anxiety and depressive disorders is limited. This study aimed to test the hypothesis that prenatal cannabis use is associated with child anxiety or depressive disorder diagnoses.
Method:
Population-based retrospective birth cohort study of children (N = 115,553) born between 1/1/2011-12/31-2017 to pregnant individuals (N = 97,376) universally screened for prenatal cannabis use. Cox proportional hazards regression models examined associations between cannabis use during early pregnancy (at ∼8-10 weeks gestation based on self-reported use or a positive urine toxicology test for delta-9-tetrahydrocannabinol [THC]) and child anxiety and depressive disorders from ages 6 to 13 years based on diagnosis codes, adjusting for maternal sociodemographic and clinical characteristics.
Results:
The median age at pregnancy onset was 31 (inter quartile range [IQR] = 6) years. Most pregnancies (61.4%) were to non-White individuals; 4.4% screened positive for any cannabis use; 3.7% had a positive toxicology test and 1.9% self-reported use. Overall, 9,230 children were diagnosed with an anxiety disorder at median age of 8 (IQR = 3) years and 1,224 with depressive disorder at median age of 9 (IQR = 3) years. Prenatal cannabis use was associated with a lower risk of child anxiety disorders (aHR:0.84, 95%CI: 0.75-0.95), which remained significant when defined by a toxicology test but not by self-report. Maternal prenatal cannabis use was not associated with child depressive disorders (aHR:1.15, 95%CI: 0.85-1.54).
Conclusions:
Prenatal cannabis use during early pregnancy was not associated with an increased risk of offspring early onset anxiety or depressive disorders.
Related Concept Videos
Stress and Mental Health
Individuals with depression often experience challenges in both their personal and professional...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
CNS Depressants: Alcohol and Nicotine
